A Study of JNJ-75220795 in Japanese Participants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05039710 |
Recruitment Status :
Terminated
(Business Judgement)
First Posted : September 9, 2021
Last Update Posted : May 16, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fatty Liver | Drug: JNJ-75220795 Other: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 in Japanese Participants |
Actual Study Start Date : | November 8, 2021 |
Actual Primary Completion Date : | February 17, 2023 |
Actual Study Completion Date : | February 22, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1: JNJ-75220795 or Placebo
Participants will receive single subcutaneous (SC) dose of JNJ-75220795 Dose 1 or matching placebo on Day 1 in Cohort 1.
|
Drug: JNJ-75220795
JNJ-75220795 will be administered as SC injection. Other: Placebo Matching placebo will be administered as SC injection. |
Experimental: Cohort 2: JNJ-75220795 or Placebo
Participants will receive single SC dose of JNJ-75220795 Dose 2 or matching placebo on Day 1 in Cohort 2.
|
Drug: JNJ-75220795
JNJ-75220795 will be administered as SC injection. Other: Placebo Matching placebo will be administered as SC injection. |
- Number of Participants with Treatment-emergent Signs and Symptoms/Adverse Events (AEs) [ Time Frame: Up to Day 168 ]Number of participants with treatment-emergent signs and symptoms/adverse events (including allergic reactions/hypersensitivity and local injection site reactions) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Treatment-emergent adverse events (TEAEs) are defined as AEs with onset or worsening on or after date of first dose of study treatment.
- Number of Participants With Change From Baseline in Vital Signs Abnormalities [ Time Frame: Baseline, Up to Day 168 ]Number of participants with change from baseline in vital signs abnormalities including body temperature (axillary), pulse, respiratory rate and blood pressure will be reported.
- Number of Participants With Change From Baseline in Clinical Laboratory Abnormalities [ Time Frame: Baseline, Up to Day 168 ]Number of participants with change from baseline in clinical laboratory abnormalities including hematology, serum chemistry and urinalysis will be reported.
- Number of Participants With Change From Baseline in Physical Examination Abnormalities [ Time Frame: Baseline, Up to Day 168 ]Number of participants with change from baseline in physical examination abnormalities will be reported.
- Number of Participants With Change From Baseline in Electrocardiogram (ECG) Abnormalities [ Time Frame: Baseline, Up to Day 168 ]Number of participants with change from baseline in ECG abnormalities will be reported.
- Percent Change in Liver Fat Content Measured by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) [ Time Frame: From Baseline to Weeks 6, 12, 18, and 24 ]Percent change in liver fat content as measured by MRI-PDFF will be reported.
- Maximum Observed Plasma Concentration (Cmax) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]Cmax of JNJ-75220795 will be reported.
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]Tmax of JNJ-75220795 will be reported.
- Apparent Elimination Half-Life (t1/2) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]t1/2 is defined as apparent elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve.
- Area Under the Plasma Concentration Time Curve of JNJ-75220795 from Time Zero to Infinite time (AUC [0-Infinity]) [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]AUC (0-Infinity) is defined as the area under the plasma concentration versus time curve of JNJ-75220795 from time zero to infinite time.
- Area Under the Plasma Concentration versus Time Curve of JNJ-75220795 from Time Zero to Time of the Last Measurable Concentration (AUC [0-Last]) [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]AUC (0-Last) is defined as area under the plasma concentration versus time curve of JNJ-75220795 from time zero to time of the last measurable concentration.
- Total Apparent Clearance (CL/F) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]CL/F is defined as total apparent clearance of JNJ-75220795.
- Apparent Volume of Distribution (Vd/F) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]Vd/F is defined as apparent volume of distribution of JNJ-75220795.
- Number of Participants with Treatment Emergent Anti-drug Antibody (ADA) [ Time Frame: Up to Day 168 ]Number of participants with treatment emergent ADA will be reported.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants with certain genetic predispositions to non-alcoholic fatty liver disease (NAFLD) determined at screening
- Presence of liver steatosis at screening
- Participants on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications must be on stable dose(s) for at least 4 weeks prior to screening
- Body mass index between 18 kilograms per meter square (kg/m^2) and 40 kg/m^2 inclusive, and body weight stable defined as no more than 5 percent (%) body weight loss or gain within 3 months prior to screening (based on participant's report) and no more than 5% body weight loss or gain from screening to randomization
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to excipients
- History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HbsAg or anti-HCV at screening. And/or history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV or syphilis at screening
- Participants with clinical or biochemical (international normalized ratio [INR] greater than [>] 1.2, or platelet count less than [<] lower limits of normal [LLN]) evidence of hepatic decompensation at screening or baseline
- Estimated glomerular filtration rate (eGFR) by Japanese eGFR formula below 60 milliliters per minute [mL/min] at screening
- Thyroid stimulating hormone (TSH) levels, free triiodothyronine (FT3) and free thyroxine (FT4) outside normal limits of the clinical laboratory's reference range at screening
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05039710
Japan | |
Souseikai Fukuoka Mirai Hospital | |
Fukuoka-shi, Japan, 813-0017 | |
Corporation Heishinkai ToCROM Clinic | |
Shinjuku-ku, Japan, 160-0008 | |
Corporation Heishinkai OCROM Clinic | |
Suita-city, Japan, 565-0853 | |
Sumida Hospital | |
Tokyo, Japan, 130-0004 |
Study Director: | Janssen Pharmaceutical K.K., Japan Clinical Trial | Janssen Pharmaceutical K.K. |
Responsible Party: | Janssen Pharmaceutical K.K. |
ClinicalTrials.gov Identifier: | NCT05039710 |
Other Study ID Numbers: |
CR109081 75220795NAS1002 ( Other Identifier: Janssen Pharmaceutical K.K., Japan ) |
First Posted: | September 9, 2021 Key Record Dates |
Last Update Posted: | May 16, 2023 |
Last Verified: | May 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu |
URL: | https://www.janssen.com/clinical-trials/transparency |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Fatty Liver Liver Diseases Digestive System Diseases |